N@N

ELAN CORP PLC -SPONS ADR (NYSE:ELN), Down By 8.35% ($0.57) From $6.830 After BUYINS.NET Report Predicted Weakness After Earning

^{Published on 2011-02-24 09:30:53 - WOPRAI}
 

February 24, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Monday, February 7th 2011 stating that ELAN CORP PLC -SPONS ADR (NYSE:ELN) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=eln&id=145154

At the time this story was written, ELAN CORP PLC -SPONS ADR (NYSE:ELN) is Down By 8.35% ($0.57) From $6.830 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

ELAN CORP PLC -SPONS ADR (NYSE:ELN) - Elan Corporation, plc operates as a neuroscience-based biotechnology company primarily in Ireland and the United States. It operates in two segments, BioNeurology and Elan Drug Technologies (EDT). The BioNeurology segment engages in the research, development, and commercial activities primarily in the areas of Alzheimers disease, Parkinsons disease, multiple sclerosis (MS), Crohns disease, and severe chronic pain. Its offers Tysabri to treat relapsing forms of MS; Prialt, a non-opioid and intrathecal analgesic for the treatment of severe chronic pain, principally neuropathic pain; Azactam, a monobactam to treat pneumonia, post-surgical infections, and septicemia; and Maxipime, an injectable cephalosporin antibiotic used to treat patients with serious and/or life-threatening infections. This segment in collaboration with Biogen Idec, Inc., develops and markets Tysabri for the treatment for Crohns disease. It also develops beta amyloid immunotherapies for the treatment of Alzheimers disease through collaboration with Wyeth. In addition, this segment develops ELND005, a novel therapeutic agent, which is in Phase II clinical study to treat Alzheimers disease; ELND006, a small molecule gamma secretase inhibitor is in Phase I clinical studies for the treatment of Alzheimers disease; and Beta secretase, a precursor to plaque development in the brain. Further, BioNeurology segment has collaboration agreement with PharmatrophiX to develop small molecule ligands for growth factor receptors relevant to neurological disorders. The EDT segment offers pharmaceutical products using its proprietary drug technologies. It also provides formulation development services and contract manufacturing services that include analytical development, clinical trial manufacturing, scale-up, product registration support, and supply chain management. Elan Corporation sells its products primarily to drug wholesalers. The company was founded in 1969 and is headquartered in Dublin, Ireland.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. ELAN CORP PLC -SPONS ADR (NYSE:ELN) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net